Page 3 of 212
The HIF-1α antisense long non-coding RNA drives a positive feedback loop of HIF-1α mediated transactivation and glycolysis
Zheng F, Chen J, Zhang X, Wang Z, Chen J, Lin X, Huang H, Fu W, Liang J, Wu W, Li B, Yao H, Hu H, Song E. Nat Commun. 2021 Feb 26;12(1):1341. Pubmed
March 15, 2021
Recent progress in non-native nucleic acid modifications
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
April 23, 2021
Antisense Technology: A Review.
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
March 15, 2021
Best practices to ensure robust investigation of circular RNAs: pitfalls and tips
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
April 23, 2021
Page 3 of 212
Page 3 of 212
The HIF-1α antisense long non-coding RNA drives a positive feedback loop of HIF-1α mediated transactivation and glycolysis
Zheng F, Chen J, Zhang X, Wang Z, Chen J, Lin X, Huang H, Fu W, Liang J, Wu W, Li B, Yao H, Hu H, Song E. Nat Commun. 2021 Feb 26;12(1):1341. Pubmed
March 15, 2021
Recent progress in non-native nucleic acid modifications
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
April 23, 2021
Antisense Technology: A Review.
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
March 15, 2021
Best practices to ensure robust investigation of circular RNAs: pitfalls and tips
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
April 23, 2021
Page 3 of 212
